Aveo Pharmaceuticals Inc

AVEO 
(NASDAQ) 
 
$ 0.6779 <%= Resources.Global.txtUp %>
Updated 19/08/2019
Change % 0.43% Stock price increasing
Change 0.0029 Stock price increasing
Volume 519,884
High $ 0.6972
Low $ 0.6694
Open $ 0.6797
ISIN
Prev close $ 0.6750
# of shares 160.74M
Market cap 108.97M USD
Intraday

Market closed
Aveo Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  0.68 2.5% Stock price increasing -4.5% Stock price decreasing -3.2% Stock price decreasing 7.8% Stock price increasing -71.4% Stock price decreasing
Powered by TradingView

News about Aveo Pharmaceuticals Inc

  • English
  • Regulatory news
26 Apr
 
25 Apr
 
25 Apr
 
23 Apr
 
23 Apr
 
19 Apr
 
18 Apr
 
18 Apr
 
16 Apr
 
16 Apr
 

Company profile

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America. Tivozanib is approved in the European Union as well as Norway and Iceland for the first-line treatment of adult patients with RCC.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 August 2019 11:06:40
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB7 - 2019-08-21 12:06:40 - 2019-08-21 11:06:40 - 1000 - Website: OKAY